drugset

drugset / Trial / NCT06419608

Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

NCT06419608 ↗

Phase 2 Completed 336 enrolled Biohaven Therapeutics Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)

Timeline

Start: 2024-05-28
Primary completion: 2025-11-07
Completion: 2025-11-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BHV-7000	Unknown	75 mg	—

Indications